At what enterprise value was PROSYS acquired in 2026?

You can find the full valuation details of PROSYS on mynth capital. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 14.8x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of PROSYS when it was acquired by IMA GROUP?

The exact EV/EBITDA multiple for PROSYS is available on mynth capital. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 14.8x. Join our community for free to access full valuation data and industry trends.

When was PROSYS acquired by IMA GROUP?

PROSYS was acquired by IMA GROUP in 2026.

What was the revenue of PROSYS at the time of the deal?

The revenue of PROSYS at the time of the deal is estimated to be in the range of 1b - 3b EUR. Register for free to access the full transaction report and exact valuation multiples.

What was the EBITDA of PROSYS during the acquisition?

PROSYS's EBITDA is estimated to be in the range of 250M - 500M EUR. Join our community for free to access complete and exact deal data.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the PROSYS acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the PROSYS deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://ima.it/en/ima-acquires-prosys/

← DATABASE

Home Database Healthcare & PharmaPROSYS

02/2026

PROSYS acquired by IMA GROUP

IRELAND Life Sciences / Medical Devices REV 1b - 3b EUR

Context

IMA Group acquired a majority stake in ProSys Sampling Systems Limited from its co-founder and Treysa Limited. The transaction is a core component of IMA's international growth strategy, aiming to strengthen its "IMA Life" division by integrating specialized containment and sampling expertise. ProSys will continue to operate as an independent business from its headquarters in Ireland, with Michael McLoughlin remaining as Managing Director. This acquisition follows IMA's August 2024 purchase of Sarong's packaging divisions, further consolidating IMA's leadership in the advanced biopharmaceutical technology segment.

PROSYS, which reported an EBITDA margin of LOGIN in 2025, is valued in this transaction at an EV/EBITDA multiple of LOGIN, a level to compare with the average currently observed in the Healthcare & Pharma sector (14.8x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

ProSys is a leading global supplier of specialized aseptic and containment isolator technology and sampling systems. Founded in 1997, the company designs and manufactures "Engineered to Order" (EtO) systems for the safe handling of highly potent compounds, serving biopharmaceutical giants like Pfizer, GSK, and Eli Lilly.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2025

2024

Similar deals in Healthcare & Pharma

List of similar M&A transactions (Date, Acquirer, Target, Country, Sector, Deal Context)
Date	Acquirer	Target	Country	Sector	Deal Context
03/2026	SIPAREX	WINNCARE	FRANCE	Life Sciences	Siparex has reaffirmed its commitment to Winncare by leading a quaternary LBO to retain control of the medical device manufacturer. This transaction allows Siparex, which originally acquired the company in 2021 via its ETI 5 fund, to extend the maturity of its investment while slightly increasing its ownership stake alongside the management team led by President Laurent Faugères
03/2026	RESONETICS	RESOLUTION MEDICAL	UNITED STATES	Life Sciences	The acquisition of Resolution Medical by Resonetics signifies a major step in the group’s expansion toward a comprehensive, full-lifecycle service model. The strategic rationale for this transaction centers on an "integrated-platform" maneuver, merging the target’s technical operational depth in biosimulation and cleanroom assembly with the acquirer’s established scale in laser-based component manufacturing and battery systems
02/2026	NORD HOLDING	HALLMARQ VETERINARY IMAGING	UNITED KINGDOM	Life Sciences	NORD Holding have acquired Hallmarq Veterinary Imaging from August Equity to merge it with German-based OR Technology. The transaction establishes a new, globally active imaging technology holding company in the veterinary sector
02/2026	CIMG	DAREN TECHNOLOGY	CHINA	Life Sciences	CIMG, through its subsidiary DZR, signed an agreement to acquire 100% of Daren Technology for approximately $40M in stock. The transaction features a highly structured Phased Payment consideration (6%, 14%, 28%, and 52%) released over 3
02/2026	VIVO CAPITAL	DUTSCHER	FRANCE	Life Sciences	Vivo Capital acquired a majority stake in Dutscher from LBO France. LBO France had acquired the asset in July 2020 from Five Arrows (Rothschild) for an enterprise value of EUR100-150M (investing EUR60M in equity)
01/2026	YOTTA CAPITAL	VILLARD	FRANCE	Life Sciences	Yotta Capital Partners led a majority buyout of Villard, succeeding the previous sponsorless structure held by CEO. The transaction values the company on a solid growth trajectory, with the management team and historical regional partners reinvesting in the new pool
01/2026	FAGRON	UNIVERSITY COMPOUNDING PHARMACY (UCP)	UNITED STATES	Life Sciences	Fagron acquired 100% of University Compounding Pharmacy for an Enterprise granting to Fagron a stronghold in California (a high-barrier market) and adds complementary therapeutic expertise (Urology) to its existing US portfolio (which includes Anazao)
12/2025	CHARTERHOUSE	WINBACK	FRANCE	Life Sciences	Charterhouse Capital Partners acquired a majority equity stake in Winback following a competitive process that attracted interest from several top-tier private equity funds. This transaction facilitates the exit of Capza, which had supported the company since late 2021 through a minority "flex equity" structure, and allows the founding duo to cash out a portion of their holdings while reinvesting to remain significant minority shareholders and operational leaders
11/2025	ANJAC BEAUTY & HEALTH	HEALTH CHAIN GROUP (HCG)	SLOVENIA	Life Sciences	Anjac acquired a majority stake in HCG to accelerate its growth in the nutraceutical space. This is the 17th company to join the Anjac ecosystem. Beyond the acquisition cost, Anjac has committed to a EUR25M investment plan to expand the Velenje production site, aiming to triple its output within 12 months
11/2025	ARLANE	DESSINTEY	FRANCE	Life Sciences	Arlane has acquired a majority stake (approximately two-thirds) in Dessintey through a primary LBO. The transaction allows for the exit of early-stage investors Turenne Sante (via Relyens Innovation Sante) and Credit Agricole Haute-Loire, who invested in 2019

REFERENCES

Revenue range: 1b - 3b EUR

EBITDA range: 250M - 500M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of PROSYS by IMA GROUP are reserved for mynth community members. Register for free to unlock full data.

Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).

Acquirer: ima group